Predicting cognitive decline with non-clinical markers in Parkinson's disease (PRECODE-2).


Journal

Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161

Informations de publication

Date de publication:
May 2019
Historique:
received: 14 09 2018
accepted: 16 02 2019
revised: 05 02 2019
pubmed: 2 3 2019
medline: 14 8 2019
entrez: 2 3 2019
Statut: ppublish

Résumé

To investigate whether baseline [ 262 de novo PD patients from the Parkinson's Progression Markers Initiative database were stratified into two CI groups at the 36-month follow-up: MoCA-defined diagnosis: PD patients who had a MoCA score < 26; neuropsychological test-defined diagnosis: PD patients with MoCA-defined diagnosis and at least two test scores (of six; irrespective of test domain) greater than 1.5 standard deviation below the mean score in healthy controls. Predictive variables of CI were divided into deciles, providing us with ideal cutoff values for each variable. At the 36-month follow-up, 108/262 (41.2%) PD patients had CI as defined by the MoCA, of which 40/108 (37.0%) had neuropsychological test-defined CI. Baseline CSF Aβ42 (hazard ratio [HR]: 0.996, confidence interval [CI]: 0.992-0.999, p = 0.025), CSF total tau ([HR]: 1.023, [CI]: 1.002-1.044, p = 0.031) and caudate [ We report a characteristic profile (reduced CSF Aβ42, increased CSF total tau and reduced caudate [

Identifiants

pubmed: 30820739
doi: 10.1007/s00415-019-09250-y
pii: 10.1007/s00415-019-09250-y
pmc: PMC6469665
doi:

Substances chimiques

Amyloid beta-Peptides 0
Amyloid beta-Protein Precursor 0
Apolipoprotein A-I 0
Peptide Fragments 0
Tropanes 0
amyloid beta-protein (1-42) 0
2-carbomethoxy-8-(3-fluoropropyl)-3-(4-iodophenyl)tropane 155797-99-2
Epidermal Growth Factor 62229-50-9
Insulin-Like Growth Factor I 67763-96-6

Types de publication

Journal Article Multicenter Study

Langues

eng

Pagination

1203-1210

Références

Arch Neurol. 2000 Apr;57(4):470-5
pubmed: 10768619
J Neurochem. 2002 Apr;81(2):229-36
pubmed: 12064470
Arch Neurol. 2003 Mar;60(3):387-92
pubmed: 12633150
Ann Neurol. 2006 Mar;59(3):512-9
pubmed: 16372280
Mov Disord. 2006 Sep;21(9):1343-9
pubmed: 16721732
J Neurol Sci. 2006 Oct 25;248(1-2):68-71
pubmed: 16782131
Acta Neuropathol. 2008 Apr;115(4):417-25
pubmed: 18185940
Acta Neuropathol. 2008 Apr;115(4):427-36
pubmed: 18273624
Parkinsonism Relat Disord. 2009 Feb;15(2):88-93
pubmed: 18434233
Neurology. 2008 Sep 16;71(12):903-10
pubmed: 18794492
J Neurol Sci. 2010 Feb 15;289(1-2):18-22
pubmed: 19733364
Mov Disord. 2009 Nov 15;24(15):2203-10
pubmed: 19795497
J Neurol Neurosurg Psychiatry. 2010 Oct;81(10):1080-6
pubmed: 20547614
Int J Alzheimers Dis. 2010 Jun 23;2010:null
pubmed: 20721349
Mov Disord. 2010 Nov 15;25(15):2682-5
pubmed: 20818673
Lancet Neurol. 2010 Dec;9(12):1200-1213
pubmed: 20880750
Prog Neurobiol. 2011 Dec;95(4):629-35
pubmed: 21930184
Curr Opin Neurol. 2012 Aug;25(4):460-5
pubmed: 22772875
Mov Disord. 2012 Sep 15;27(11):1392-7
pubmed: 22976926
Parkinsonism Relat Disord. 2013 Aug;19(8):717-24
pubmed: 23643469
JAMA Neurol. 2013 Oct;70(10):1277-87
pubmed: 23979011
Neurology. 2014 May 20;82(20):1784-90
pubmed: 24748671
Ann Neurol. 1989 Jul;26(1):47-50
pubmed: 2549846
Mov Disord. 2015 Jun;30(7):919-27
pubmed: 25737166
J Parkinsons Dis. 2015;5(4):783-92
pubmed: 26599300
JAMA Neurol. 2016 Nov 1;73(11):1334-1341
pubmed: 27654968
PLoS One. 2017 May 17;12(5):e0175674
pubmed: 28520803
Neurology. 1985 Oct;35(10):1506-9
pubmed: 3875807
Arch Neurol. 1997 Feb;54(2):145-50
pubmed: 9041855
Stroke. 1997 May;28(5):970-5
pubmed: 9158635

Auteurs

Tayyabah Yousaf (T)

Neurodegeneration Imaging Group, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), Maurice Wohl Clinical Neuroscience Institute, King's College London, 125 Coldharbour Lane, Camberwell, London, SE5 9NU, UK.

Gennaro Pagano (G)

Neurodegeneration Imaging Group, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), Maurice Wohl Clinical Neuroscience Institute, King's College London, 125 Coldharbour Lane, Camberwell, London, SE5 9NU, UK.

Flavia Niccolini (F)

Neurodegeneration Imaging Group, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), Maurice Wohl Clinical Neuroscience Institute, King's College London, 125 Coldharbour Lane, Camberwell, London, SE5 9NU, UK.

Marios Politis (M)

Neurodegeneration Imaging Group, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), Maurice Wohl Clinical Neuroscience Institute, King's College London, 125 Coldharbour Lane, Camberwell, London, SE5 9NU, UK. marios.politis@kcl.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH